Rigel Pharmaceuticals Reports Impressive Financial Results for 2025 with Robust Growth and A Promising Future Rigel Pharmaceuticals announces strong financial results for Q4 and FY 2025, highlighting significant growth in product sales and a positive outlook for 2026.

Rigel Pharmaceuticals Reports Impressive Financial Results for 2025 with Robust Growth and A Promising Future #USA #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #GAVRETO

Rigel Pharmaceuticals Announces Positive 2025 Revenues and 2026 Projections Rigel Pharmaceuticals reveals a promising business update for 2025, highlighting substantial revenue growth and optimistic projections for continued expansion in 2026.

Rigel Pharmaceuticals Announces Positive 2025 Revenues and 2026 Projections #United_States #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #GAVRETO

Rigel Pharmaceuticals Announces Robust Q3 2025 Financial Results and Strategic Outlook In the third quarter of 2025, Rigel Pharmaceuticals reported impressive financial results, showcasing significant revenue growth and a strong business outlook.

Rigel Pharmaceuticals Announces Robust Q3 2025 Financial Results and Strategic Outlook #United_States #South_San_Francisco #Rigel_Pharmaceuticals #R289 #TAVALISSE

Rigel Pharmaceuticals Announces Strong Financial Growth and Clinical Progress in Q2 2025 Rigel Pharmaceuticals reports impressive financial results for Q2 2025, with $101.7 million in total revenue and significant pipeline advancements in hematology and oncology.

Rigel Pharmaceuticals Announces Strong Financial Growth and Clinical Progress in Q2 2025 #United_States #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #GAVRETO

Rigel Pharmaceuticals Reports Impressive First Quarter Performance and Strategic Updates In its first quarter of 2025, Rigel Pharmaceuticals achieved approximately $53.3 million in revenue, marking a significant increase and promising growth in clinical development.

Rigel Pharmaceuticals Reports Impressive First Quarter Performance and Strategic Updates #USA #South_San_Francisco #Rigel_Pharmaceuticals #R289 #TAVALISSE

Rigel Pharmaceuticals Settles Patent Dispute Over TAVALISSE® with Annora Pharma Rigel Pharmaceuticals has reached a settlement with Annora Pharma regarding patent litigation over TAVALISSE®, allowing for potential market entry of a generic version by 2032.

Rigel Pharmaceuticals Settles Patent Dispute Over TAVALISSE® with Annora Pharma #United_States #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #Annora_Pharma

Rigel Pharmaceuticals Releases Impressive Q4 and Full Year 2024 Financial Results Amidst Strong Business Expansion Rigel Pharmaceuticals reports significant revenue growth for Q4 2024, driven by strong product sales and successful regulatory achievements, projecting a promising 2025 outlook.

Rigel Pharmaceuticals Releases Impressive Q4 and Full Year 2024 Financial Results Amidst Strong Business Expansion #USA #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #REZLIDHIA

Rigel Pharmaceuticals Reflects on 2024 Milestones and Sets Ambitious Goals for 2025 Rigel Pharmaceuticals has announced a successful 2024 with significant revenue growth, new product sales, and a hopeful outlook for 2025 as they continue to expand their hematology and oncology pipeline.

Rigel Pharmaceuticals Reflects on 2024 Milestones and Sets Ambitious Goals for 2025 #USA #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #REZLIDHIA